ebov

SP187 (MON-DNJ) is a host-targeted iminosugar. It has anti-filovirus infection activity.SP187 is used for therapeutic use against influenza and dengue viruses.

FGI-106 tetrahydrochloride demonstrates potent inhibitory activity across a broad spectrum of viruses, including those causing hemorrhagic fevers such as Ebola, Rift Valley, and Dengue Fever, with half-maximal effective concentrations (EC50s) of 100 nM, 800 nM, and 400-900 nM, respectively. Additionally, it effectively inhibits non-hemorrhagic fever viruses, notably HCV and HIV-1, with EC50s of 200 nM and 150 nM, respectively, indicating its broad-spectrum antiviral potential.

EBOV-IN-1 is an adamantane dipeptide piperazine inhibitor against Ebola virus (EBOV) that inhibits EBOV infection and suppresses pseudotypic EBOV infection.

EBOV-IN-10 is an orally active inhibitor of the Ebola virus (EBOV) with an EC50 value of 0.19 μM.

EBOVentry-IN-1 (compound Hu7) is an inhibitor of EBOV virus entry, with an IC50 of 1.50 μM.

EBOV-IN-2 (Compound 2) is an inhibitor of the Ebola virus (EBOV), with IC50 values of 0.37 μM for Ebola virus glycoprotein pseudotyped virus (pEBOV) and 2.54 μM for African Swine Fever Virus (ASFV).

EBOV-IN-6 (compound 19) is a benzothiazole compound. It demonstrates antiviral activity against pEBOV, with an IC50 value of 10 μM.

EBOV-IN-9 (compound 2b) is a Diphyllin derivative that inhibits Ebola virus entry with an EC50 of 40 nM. It effectively combats EBOV-infected monocyte-derived macrophages, showing an EC50 of 107 nM.

EBOVentry-IN-2 (compound 16) is an inhibitor of EBOV entry with an EC50 value of 4.42 μM and demonstrates metabolic stability.

EBOV-GP-IN-1 (Compound 28) is a potent inhibitor of Ebola virus entry, targeting the Ebola virus envelope glycoprotein (EBOV-GP) with an IC50 of 0.05 μM.

EBOV-IN-C31 is a novel PP1-targeting Ebola Virus (EBOV) inhibitor with improved pharmacological properties.

EBOV-IN-8 (Compound 30) effectively inhibits the Ebola pseudotyped virus (pEBOV) with an inhibition concentration (IC 50) of 62.1% at a dosage of 10 μM [1].

EBOV-IN-3 (compound 9), a benzothiazepine compound, and EBOV-IN-6 exhibit notable anti-pEBOV activity, with the latter demonstrating an IC 50 value of 0.37 μM [1].

EBOV-IN-4 (compound 12), a benzothiazepine, acts as a potent inhibitor against the Ebola virus (EBOV), displaying 64.9% inhibitory activity against EBOV-GP-pseudotype virus (pEBOV) at a concentration of 10 μM. It is, however, inactive against ASFV [1].

EBOV-IN-5 (compound 14) serves as an antiviral agent targeting the Ebola virus (EBOV) by disrupting its entry mechanism into host cells. It specifically blocks the interaction between the EBOV glycoprotein EBOV-GPcl and the essential host receptor NPC1, which is crucial for the virus's fusion and entry into the cell. [7] [1]

EBOV-IN-7 (compound 26) acts as an inhibitor against the Ebola virus EBOV, displaying an IC 50 value of 2.04 μM against pEBOV (EBOV-GP pseudotyped virus). It also obstructs the EBOV-GPcl/NPC1 interaction and exhibits inhibitory effects on cancer cells. [8] [1]

FGI-106 is a potent, broad-spectrum inhibitor demonstrating activity against various viruses, including Ebola, Rift Valley Fever, and Dengue Fever, exhibiting EC50 values of 100 nM, 800 nM, and 400-900 nM, respectively. Furthermore, it effectively inhibits non-hemorrhagic fever viruses such as HCV and HIV-1, with EC50s of 200 nM and 150 nM, respectively.

R 59-022 (DKGI-I) is a diacylglycerol kinase (DGK) inhibitor and a 5-HT Receptor antagonist that blocks filovirus internalization in host cells. R 59-022 activates protein kinase C (PKC), inhibits intestinal smooth muscle contractility, and enhances O2- production induced by 1-oleoyl-2-acetylglycerol.

Retro-2 (2-{[(5-methyl-2-thienyl)methylene]amino}) is a plant toxin ricin inhibitor, itprotects HeLa cells against Ricin, Stx1 and Stx2, selectively blocks retrograde toxin trafficking at the early endosome-TGN (trans-Golgi network) interface.

Tamoxifen (Standard) is a reference standard of tamoxifen, suitable for quantitative analysis, quality control, and related research such as biochemical experiments. Tamoxifen is an orally active selective estrogen receptor modulator (SERM) that acts as an antagonist to estrogen in mammary cells and as an agonist in bone, liver, and uterine cells. Tamoxifen (Standard) can be used to induce gene knockout and liver injury models in mice, and possesses various biological activities, including the activation of Hsp90, inducing autophagy and apoptosis, and inhibiting EBOV (IC50 = 0.1 μM) and MARV (IC50 = 1.8 μM) viral infections.

Anti-Human/Mouse/Bovine LAG-3 Antibody (ADI-31853) is a monoclonal inhibitory antibody targeting human, mouse, and bovine LAG-3, which can be used in cancer immunotherapy research.

Anti-Human/Mouse/Bovine ADAM10 Antibody (8C7) is a monoclonal inhibitory antibody targeting human, mouse and bovine ADAM10 protein, which can be used in immunological research.

Anti-Mouse/Human/Rat/Monkey/Hamster/Canine/Bovine TGF-β Antibody (1D11.16.8) is an IgG antibody inhibitor targeting TGF-β in multiple species including mouse, human, rabbit, monkey, hamster, dog, and cow. For information on the isotype control, refer to Mouse IgG1 kappa, Isotype Control.

Melamine-Bov IgG is a hapten-carrier protein conjugate formed by coupling Melamine to bovine immunoglobulin (bovIgG). As a hapten, Melamine alone cannot induce an immune response and must be conjugated to a large molecular protein to become a complete antigen with immunogenicity. Melamine-Bov IgG may be supplied as a lyophilized powder or as a solution. The solution is prepared in 0.01 M TBS (pH 7.4) buffer.